These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33555543)

  • 1. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors.
    Gassenmaier M; Lenders MM; Forschner A; Leiter U; Weide B; Garbe C; Eigentler TK; Wagner NB
    Target Oncol; 2021 Mar; 16(2):197-205. PubMed ID: 33555543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
    Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
    Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status.
    Frauchiger AL; Mangana J; Rechsteiner M; Moch H; Seifert B; Braun RP; Dummer R; Goldinger SM
    Br J Dermatol; 2016 Apr; 174(4):823-30. PubMed ID: 26659191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
    Wagner NB; Forschner A; Leiter U; Garbe C; Eigentler TK
    Br J Cancer; 2018 Aug; 119(3):339-346. PubMed ID: 29950611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
    Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis.
    Petrelli F; Ardito R; Merelli B; Lonati V; Cabiddu M; Seghezzi S; Barni S; Ghidini A
    Melanoma Res; 2019 Feb; 29(1):1-12. PubMed ID: 30308577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.
    Chan MM; Haydu LE; Menzies AM; Azer MW; Klein O; Lyle M; Clements A; Guminski A; Kefford RF; Long GV
    Cancer; 2014 Oct; 120(20):3142-53. PubMed ID: 24985732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.
    Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A
    Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors.
    Cocorocchio E; Martinoli C; Gandini S; Pala L; Conforti F; Stucchi S; Mazzarol G; Ferrucci P
    Clin Transl Oncol; 2020 Oct; 22(10):1818-1824. PubMed ID: 32108276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
    Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
    Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum S100B levels correlate with stage, N status, mitotic rate and disease outcome in melanoma patients independent to LDH.
    Karonidis A; Mantzourani M; Gogas H; Tsoutsos D
    J BUON; 2017; 22(5):1296-1302. PubMed ID: 29135116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
    Schiltz PM; Dillman RO; Korse CM; Cubellis JM; Lee GJ; De Gast GC
    Cancer Biother Radiopharm; 2008 Apr; 23(2):214-21. PubMed ID: 18454690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors.
    Teterycz P; Jagodzińska-Mucha P; Cybulska-Stopa B; Mariuk-Jarema A; Kozak K; Koseła-Paterczyk H; Czarnecka AM; Rajczykowski M; Dziura R; Galus Ł; Mackiewicz J; Świtaj T; Klimczak A; Falkowski S; Suwiński R; Ziobro M; Ługowska I; Rutkowski P
    Melanoma Res; 2018 Oct; 28(5):435-441. PubMed ID: 29782381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
    Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
    Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
    Rozeman EA; Versluis JM; Moritz R; Wilgenhof S; van Thienen JV; Haanen JBAG; van de Heuvel MM; Blank CU; van Rossum HH
    Clin Chim Acta; 2022 Aug; 533():71-78. PubMed ID: 35709988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
    Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
    Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1.
    Janka EA; Ványai B; Szabó IL; Toka-Farkas T; Várvölgyi T; Kapitány A; Szegedi A; Emri G
    Front Oncol; 2023; 13():1237643. PubMed ID: 37664072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
    Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
    Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.